A Phase I Trial of RX-0201 (Archexin; Akt-1 Antisense) in Patients With an Advanced Cancer
AKT-1, the expression protein product of akt-1 protooncogene, plays a vital role in cancer progression by stimulating proliferation and inhibiting apoptosis of cancer cells. RX-0201 (Archexin), a 20-mer oligonucleotide with sequence complementary to akt-1 mRNA, is designed to inhibit the expression of akt-1 within cancer cells in cancer patients (Pts). Non-clinical studies conducted on RX-0201 demonstrated that RX-0201 bears significant in vitro and in vivo anti-cancer activities with favorable safety.
Book a meeting or send us a message to talk to one of our experts.